Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions

[1]  N. Isoherranen,et al.  Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions , 2013, Drug Metabolism and Disposition.

[2]  Lu Wang,et al.  Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes. , 2013, Chirality.

[3]  P. Gennemark,et al.  Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  S-M Huang,et al.  Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials , 2012, Clinical pharmacology and therapeutics.

[5]  L Zhang,et al.  Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time‐Dependent CYP3A Inhibitor , 2012, Clinical pharmacology and therapeutics.

[6]  Shiew-Mei Huang,et al.  PBPK as a tool in regulatory review. , 2012, Biopharmaceutics & drug disposition.

[7]  M Rowland,et al.  The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review , 2012, Clinical pharmacology and therapeutics.

[8]  Shiew-Mei Huang,et al.  Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice , 2012, Biopharmaceutics & drug disposition.

[9]  Shiew-Mei Huang,et al.  Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.

[10]  A. Rostami-Hodjegan,et al.  The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel , 2011, Drug Metabolism and Disposition.

[11]  Z. Kovarik,et al.  Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers. , 2011, Biochimie.

[12]  J. Markowitz,et al.  Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? , 2008, Journal of clinical psychopharmacology.

[13]  Masoud Jamei,et al.  Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. , 2008, Current drug metabolism.

[14]  T. Andersson,et al.  Stereoselective Disposition of Proton Pump Inhibitors , 2008, Clinical drug investigation.

[15]  Qiao Mei,et al.  Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people , 2007, Journal of clinical pharmacy and therapeutics.

[16]  P. Neuvonen,et al.  Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen , 2007, European Journal of Clinical Pharmacology.

[17]  F. Jahansouz,et al.  Clinical Pharmacology Review , 2007 .

[18]  M. Hayakari,et al.  Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations , 2007, European Journal of Clinical Pharmacology.

[19]  T. Andersson,et al.  Enantiomer/Enantiomer Interactions between the S- and R- Isomers of Omeprazole in Human Cytochrome P450 Enzymes: Major Role of CYP2C19 and CYP3A4 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[20]  M. Kodaira,et al.  Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  T. Ishizaki,et al.  Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. , 2005, Drug metabolism and pharmacokinetics.

[22]  A. Somogyi,et al.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. , 2004, British journal of clinical pharmacology.

[23]  T. Andersson,et al.  A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[24]  M. Kasuga,et al.  Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. , 2002, Biological & pharmaceutical bulletin.

[25]  D. Brocks,et al.  Stereoselective Pharmacokinetics and Pharmacodynamics of Anti-Asthma Agents , 2002, The Annals of pharmacotherapy.

[26]  H. K. Cho,et al.  Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. , 2002, Biopharmaceutics & drug disposition.

[27]  K. Ohashi,et al.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH , 2001, Alimentary pharmacology & therapeutics.

[28]  T. Andersson,et al.  Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole , 2001, Clinical pharmacokinetics.

[29]  M Antonsson,et al.  Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  T. Andersson,et al.  Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects , 2000, European Journal of Clinical Pharmacology.

[31]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[32]  G. Batist,et al.  Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. , 1994, Cancer research.

[33]  K. Schey,et al.  Stereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[34]  T. Pallasch.  Clinical pharmacology--a review. , 1966, Journal of oral therapeutics and pharmacology.